Femasys (FEMY) AI Stock Analysis

• Market Cap: $41.39M
• Dividend Yield: N/A
• Average Volume (3M): 15.25M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: 98.61%
• EPS Growth: -1.98%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 43,009,995
• 10 Day Avg. Volume: 16,652,747
• 30 Day Avg. Volume: 15,245,921
• PEG Ratio: 0.13
• Price to Book (P/B): 10.63
• Price to Sales (P/S): 15.04
• P/FCF Ratio: -1.21
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $8.00
• Price Target Upside: 733.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.54
• Revenue Forecast (FY): $3.67M

• Rating: 49 Neutral
• Price Target: $1.00 ▲(4.17% Upside)

Femasys's overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and cash flow challenges. While technical analysis shows some short-term positive momentum, the long-term outlook remains uncertain. The valuation further reflects the company's financial difficulties, with a negative P/E ratio and no dividend yield.

Positive Factors

Revenue Growth

Strong revenue growth suggests Femasys is successfully expanding its market presence and product adoption, which is crucial for long-term business sustainability.

Innovative Product Offering

Femasys's focus on innovative non-surgical solutions provides a competitive edge in the women's health sector, potentially driving future growth and market differentiation.

Market Expansion Potential

Engaging in partnerships and licensing agreements can enhance Femasys's market reach and revenue streams, supporting long-term growth and stability.

Negative Factors

Financial Instability

Ongoing financial instability with persistent losses and negative cash flows poses a risk to Femasys's long-term viability, requiring strategic financial management.

High Leverage

High leverage can limit financial flexibility and increase risk, necessitating careful debt management to ensure long-term financial health.

Unprofitability

Sustained unprofitability with negative margins highlights operational challenges, requiring efficiency improvements to achieve profitability and sustainable growth.

Femasys Business Overview & Revenue Model

Company Description

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

How the Company Makes Money

Femasys generates revenue primarily through the sale of its medical devices and systems designed for women's reproductive health. The company's revenue model is based on direct sales to healthcare providers, hospitals, and clinics that utilize its innovative technologies. Additionally, Femasys may engage in partnerships with other healthcare organizations and distributors to expand its market reach and enhance product visibility. Key revenue streams include product sales from its core offerings and potential licensing agreements or collaborations with larger medical companies that can leverage Femasys's technology in broader applications. The company may also benefit from grants or funding aimed at supporting women's health initiatives, further contributing to its financial performance.

Femasys Financial Statement Overview

Summary

Femasys is facing financial headwinds with persistent losses and cash flow issues. While there's some revenue growth, it is overshadowed by operational inefficiencies and financial instability. Strengthening financial health and achieving profitability are crucial for future sustainability.

Income Statement

Femasys has shown a slight increase in revenue over the years, but the company remains unprofitable with consistent negative EBIT and EBITDA margins. The net profit margin remains negative, and the revenue growth rate is volatile, suggesting challenges in achieving stable growth.

Balance Sheet

The balance sheet reflects financial instability with a negative equity position in earlier years, improving to positive but weak equity levels recently. The debt-to-equity ratio indicates high leverage, which could pose risks if not managed carefully. The company needs to strengthen its equity base for financial stability.

Cash Flow

Femasys consistently experiences negative operating and free cash flows, indicating operational challenges and a reliance on external financing. The cash flow to net income ratios are unfavorable, emphasizing the company's struggle to generate cash through operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.89M	1.63M	1.07M	1.21M	1.18M	1.04M
Gross Profit	1.01M	1.08M	691.90K	764.28K	809.30K	731.38K
EBITDA	-18.34M	-16.33M	-13.17M	-10.49M	-6.55M	-5.80M
Net Income	-21.02M	-18.82M	-14.25M	-11.39M	-7.54M	-6.91M
Balance Sheet
Total Assets	2.43M	12.45M	27.76M	16.90M	28.58M	7.61M
Cash, Cash Equivalents and Short-Term Investments	3.22M	3.45M	21.72M	12.96M	24.78M	3.32M
Total Debt	7.85M	7.44M	6.70M	543.72K	990.21K	2.06M
Total Liabilities	12.27M	10.14M	9.40M	1.65M	2.24M	59.42M
Stockholders Equity	1.51M	2.30M	18.35M	15.24M	26.33M	-51.82M
Cash Flow
Free Cash Flow	-20.41M	-20.21M	-11.42M	-11.14M	-8.24M	-4.96M
Operating Cash Flow	-19.67M	-19.44M	-11.28M	-10.73M	-7.93M	-4.93M
Investing Cash Flow	-744.21K	-847.76K	-143.92K	-407.48K	-306.87K	968.32K
Financing Cash Flow	10.10M	2.03M	20.18M	-681.64K	29.70M	871.65K

Femasys Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Neutral. The current price of 0.96 is above the 20-day moving average (MA) of 0.74, above the 50-day MA of 0.57, and above the 200-day MA of 0.95, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 55.49 is Neutral, neither overbought nor oversold. The STOCH value of 60.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FEMY.

Femasys Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	58 Neutral	$7.33M	0.77	5.90%	―	-4.99%	-19.11%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FEMY	49 Neutral	$41.39M	―	-329.45%	―	98.61%	-1.98%
POCI	49 Neutral	$38.03M	-5.69	-51.78%	―	-0.07%	-74.60%
RVP	48 Neutral	$25.18M	-2.81	-10.80%	―	-0.24%	50.45%
NXGL	40 Underperform	$23.44M	-5.47	-58.34%	―	73.38%	34.87%
MLSS	38 Underperform	$29.73M	-4.35	-123.50%	―	7.84%	-43.00%

Femasys Corporate Events

Femasys Secures Major Order for FemBloc Launch

On November 6, 2025, Femasys Inc. announced a significant initial order valued at approximately $500,000 USD for the commercial launch of FemBloc Permanent Birth Control in France and the Benelux region through its partnership with Kebomed. This order marks continued progress in expanding FemBloc’s presence across key European markets, reflecting growing international momentum for this innovative, non-surgical permanent contraceptive solution. FemBloc, a first-of-its-kind non-surgical solution for permanent birth control, addresses a significant unmet need in women’s reproductive health by providing a safer, more convenient, and affordable option compared to surgical sterilization.

The most recent analyst rating on (FEMY) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Secures $12 Million Through Private Placement

Femasys Inc. announced on November 3, 2025, that it has entered into a Securities Purchase Agreement with accredited investors to raise $12 million through a private placement of senior secured convertible notes and warrants. The proceeds will be used to repay existing debt and for general corporate purposes, with company insiders participating in the investment. The agreement grants the lead lender a board nomination right and includes customary covenants and restrictions.

The most recent analyst rating on (FEMY) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Receives FDA Approval for FemBloc Trial

On November 3, 2025, Femasys Inc. announced it has received FDA approval to advance the final phase of the FemBloc trial, a non-surgical permanent birth control method, marking a significant step towards potential U.S. market entry. Additionally, Femasys secured $12 million in financing, with potential to reach $58 million, which will be used to refinance existing debt and support the commercialization of its fertility and birth control portfolio, reflecting strong investor confidence in the company’s mission to transform women’s health.

The most recent analyst rating on (FEMY) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys, Inc. Advances Non-Surgical Birth Control with FemBloc Study

Femasys, Inc. is conducting a clinical study titled FINALE: Prospective Multi-Center Trial for FemBloc INtratubal Occlusion for TranscervicAL PErmanent Birth Control. The study aims to evaluate the effectiveness of the FemBloc device for permanent birth control through intratubal occlusion. This trial is significant as it explores a non-surgical option for contraception, potentially offering a less invasive alternative for women seeking permanent birth control.

Femasys Meets Nasdaq Equity Requirement After Offering

On May 19, 2025, Femasys Inc. received a notice from Nasdaq indicating that its common stock had fallen below the minimum market value requirement for continued listing. However, after a recent offering and warrant exercises, the company reported a pro forma stockholders’ equity of approximately $5.2 million as of October 15, 2025, meeting Nasdaq’s minimum requirement. Nasdaq will continue to monitor Femasys’ compliance, and failure to maintain these standards could result in delisting.

The most recent analyst rating on (FEMY) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys COO Daniel Currie Announces Retirement

On October 13, 2025, Daniel Currie, Chief Operating Officer of Femasys Inc., announced his retirement effective December 15, 2025, after over 20 years with the company. His departure is due to personal health reasons and a desire to focus on family. The company has entered into a Separation Agreement with Currie, ensuring the vesting of unvested stock options and continuation of health benefits through 2026. The Board of Directors expressed their gratitude for his leadership and service.

The most recent analyst rating on (FEMY) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Announces $8 Million Public Offering

On August 25, 2025, Femasys Inc. entered into an underwriting agreement with JonesTrading Institutional Services LLC and Laidlaw & Company (UK) Ltd. for a public offering of shares and warrants, expecting to raise $8 million. The proceeds will be used for commercial expansion, product development, and general corporate purposes, with the offering set to close on August 27, 2025.

The most recent analyst rating on (FEMY) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Gains UK Approval for FemBloc Birth Control

On August 20, 2025, Femasys Inc. announced that it received UK regulatory approval for its FemBloc Permanent Birth Control, a non-surgical solution for permanent birth control. This approval marks a significant milestone in Femasys’ European commercialization strategy, following its recent CE mark for Europe. The approval not only validates FemBloc’s safety and effectiveness but also positions Femasys to secure a strategic partner for commercialization in the UK, a key healthcare market in Europe.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.